WALTHAM, Mass.--Genome Therapeutics and Scriptgen Pharmaceuticals have entered into a licensing agreement that will provide Scriptgen with nonexclusive access to Genome Therapeutics' proprietary microbial sequence database, PathoGenome. The database of sequence information on medically relevant microbial organisms and fungi will allow researchers at Scriptgen to identify gene targets, which it says will aid in the discovery of novel therapeutics for treating infectious diseases and drug-resistant organisms.
Scriptgen will pay annual subscription fees and milestone payments, as well as royalties on products developed as a result of the use of the database. Genome Thera peutics claimed that Patho Genome is the most comprehensive commercial source of microbial genomic information available.
The nonexclusive database is designed for use at the client site utilizing proprietary bioinformatics software developed at Genome Therapeutics. Bayer, Bristol-Myers Squibb and Schering-Plough also subscribe to PathoGenome.